Peptide education
N-Acetyl Selank Amidate
NASA
N-Acetyl Selank Amidate is Selank with the two terminal caps vendors add to many peptides: acetyl on one end, amide on the other, written Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2. It exists mainly as a gray-market product, and the first problem is knowing what you are looking at: listings disagree on CAS numbers, formulas, and molecular weights, and some reuse native Selank identifiers for this different molecule. The second problem runs deeper. Native Selank has small human anxiety studies; this analog has no published human evidence at all, so every claim about it is chemistry inference or parent-compound borrowing.
Native Selank has small human anxiety studies; this amidated version has none, and the market selling it cannot keep its own identifiers straight. Treat stronger, longer-lasting, and better brain penetration as vendor chemistry arguments, not findings.
Overview
Quick answer
Native Selank, N-acetyl Selank, and N-Acetyl Selank Amidate are distinct molecules. Native Selank is the parent peptide with Russian nasal-drop labeling and small human studies. The amidated analog is mostly visible in gray-market listings, COAs, vendor descriptions, and forum discussion that claim longer duration, stronger effects, or better brain penetration before the human analog data exist.
What is it?
A terminally modified Selank analog: the seven-amino-acid Selank sequence with an acetyl cap at the N-terminus and an amide at the C-terminus, Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2. The modifications are a standard stability strategy, but this specific molecule has never been characterized in a published study.
Why is it discussed?
Because native Selank has a Russian anxiety label and small comparator trials, and vendors sell the amidated form as the upgrade: stronger, longer-lasting, better brain penetration. The parent data is real. The upgrade is an inference from peptide chemistry, not a measurement.
What do people use or discuss it for?
Anxiety, calmer focus, stress resilience, mood, social ease, sleep-adjacent calm, and benzodiazepine-like effects without the benzodiazepine drawbacks. Those are the goals people bring to it. The demonstrated outcomes, small ones in anxiety-spectrum patients, all belong to native Selank.
What route and exposure patterns do sources report?
The only concrete human schedule is the native Selank label: intranasal drops three times daily for 14 days, plus label pharmacokinetics like 92.8% intranasal bioavailability and plasma decline over 5 to 5.5 minutes. Community amidate use runs around 100 to 300 mcg once or twice daily for 2 to 4 weeks. None of the parent numbers transfer; the analog has no measured human exposure profile.
What is the main sorting problem?
Figuring out what a listing actually is. Sellers mix native Selank, N-acetyl Selank, and the amidate under drifting names and identifiers, and purity numbers mislead: one seller example pairs 99.39% HPLC purity with only 85.50% peptide content, alongside reported water and acetate content. Identity, content, and counterions decide what a vial means before any claim about effects.
Reported practice
Commonly reported protocol
Community modified-analog ranges. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
COA and vendor material describe an acetylated and amidated Selank sequence, while public identifier coverage is inconsistent.
The cited human studies involve native Selank in anxiety-spectrum settings, not N-Acetyl Selank Amidate.
The Russian native Selank label provides the most concrete human route and schedule, but it is native Selank context, not an amidate regimen.
The native Selank Russian label describes 92.8% intranasal bioavailability, appearance in plasma within 30 seconds, brain tissue penetration, and progressive plasma decline over 5 to 5.5 minutes. Those numbers help explain the parent peptide, but they do not establish superior exposure for N-Acetyl Selank Amidate.
FDA material discusses Selank in compounding-risk and warning-letter contexts, not as an FDA-approved human drug.
COA and vendor examples show that HPLC purity, peptide content, water, acetate burden, sterility, and identity each need to be checked for the actual vial or spray.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| N-Acetyl Selank Amidate works for anxiety like Selank. | The human studies available here were for native Selank, including small Russian-language comparisons in generalized anxiety, neurasthenia, phobic-anxiety, somatoform, and anxiety-asthenic contexts. An amidate-specific randomized human trial was not found. | Native Selank mechanism papers discuss GABAergic modulation, monoamine and orexin-related gene-expression changes, enkephalinase inhibition, and immune-cytokine findings. Transfer to the amidated analog remains inferential. | Sellers and forums describe the amidated analog as calming, anxiolytic, focus-supporting, and sometimes benzodiazepine-like. Those reports show what people are seeking and how sellers position it. | The anxiety discussion mostly comes from the Selank family. Exact-analog human anxiety and safety data were not found. |
| The amidated form crosses the blood-brain barrier better than regular Selank. | No direct human brain-exposure or pharmacokinetic study for the amidated analog is available in the cited sources. | The native Selank label says the parent compound appears rapidly in plasma after intranasal use and penetrates brain tissue. Sellers extend that claim by arguing that terminal acetylation and amidation may improve stability or exposure, but direct analog evidence is not available here. | Forum and vendor claims commonly say the amidated version feels stronger or more efficient, sometimes implying better brain access. | Better brain penetration is a market claim for now. Parent-label pharmacokinetic language does not answer exact-analog brain exposure. |
| It lasts longer or is more potent because it is acetylated and amidated. | Amidate-specific human duration, dose-response, or potency data are not available in the cited sources. | Terminal modifications can plausibly change peptide stability and exopeptidase vulnerability. That chemistry rationale explains the market narrative, but it is not the same as a measured human duration or potency advantage. | Vendor pages and forums repeatedly describe longer duration, lower needed amounts, and stronger subjective effects. | Plausible chemistry logic and common seller language, but still not a measured human clinical or pharmacokinetic advantage for this exact analog. |
| It is a nootropic for focus, memory, or social calm. | Native Selank clinical summaries mention anxiolytic, antiasthenic, psychostimulant, or mild nootropic language, but the available human evidence is small and parent-compound-specific. | Native Selank papers discuss neurotransmission and gene-expression effects that can explain why cognition and focus claims appear around the Selank family. | Market pages and personal-use reports describe calm focus, less stress reactivity, social comfort, and cognitive support. | This is a common online topic, but the cited analog-specific material has not shown a cognitive-enhancement effect. |
| It is non-addictive and safer than benzodiazepines. | The native Selank Russian label states no dependence or habituation, and native clinical literature compares Selank with benzodiazepine drugs in small studies. That leaves long-term withdrawal, dependence, and comparative safety for N-Acetyl Selank Amidate unanswered. | Native Selank mechanism papers suggest GABA-system modulation without simply acting like classic sedative drugs. That may explain why benzodiazepine-comparison language appears, but it is still proxy biology. | Forums and sellers sometimes describe benzo-like calm without dependence or sedation. | Native Selank tolerability language does not automatically transfer to the amidated analog as a long-term safety guarantee. |
| A 99% purity COA verifies a current vial or spray. | Vendor COAs are product paperwork, not human safety or efficacy studies. | The issue is not receptor biology. The practical issues are identity, peptide content, water, acetate or other counterions, representative lot sampling, sterility, endotoxin, residual solvents, concentration, storage, and chain of custody. | The materials include one third-party COA with HPLC-UV-MS identity confirmation and 99.60% HPLC purity, and another seller example separating 99.39% HPLC purity from 85.50% peptide content, 2.34% water, and 15.82% acetate content. | A purity number can be useful, but it still leaves key questions unanswered: sterile handling, endotoxin control, peptide-by-mass content, counterion burden, storage, and whether the shipped lot matches the document. |
Bottom line
Main takeaway
A modified Selank sold as stronger and longer-lasting. The parent has small human anxiety studies; this version has none, and even the product paperwork is inconsistent.
Three molecules circulate under this family: native Selank, N-acetyl Selank, and N-Acetyl Selank Amidate. The human evidence belongs to the first, so check which molecule a listing claims, then whether its identifiers, formula, and peptide content agree with that claim.
The human citations here are all parent-compound papers; the amidate record is COAs, vendor pages, and anecdotes with identifier drift across listings. Potency, duration, brain penetration, and long-term safety all remain open.
Identity
What it is
Native Selank is a tuftsin-derived heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro. N-Acetyl Selank Amidate is that sequence with terminal modifications, usually written Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2.
The marketing case is simple: acetylation and amidation protect peptides from the enzymes that clip their ends, so the analog should last longer and hit harder. The chemistry reasoning is legitimate as far as it goes. What is missing is any published characterization of this molecule, in animals or people, showing it actually behaves that way.
What the human record does contain belongs to the parent: a Russian intranasal label with contraindications and pharmacokinetic numbers, and small anxiety-spectrum trials against medazepam and phenazepam. Useful context for understanding Selank. Not evidence about this analog.
The market adds a paperwork problem on top. Listings disagree on CAS numbers, formulas, and molecular weights; some reuse native Selank identifiers; purity percentages get quoted next to peptide-content figures that tell a different story. Sorting out what a given vial claims to be is real work here.
How people talk about it online
Forum and vendor talk centers on calm without sedation: less anxiety, less stress reactivity, social ease, better sleep, no benzodiazepine drawbacks. The recurring claim is that the amidated form feels stronger or lasts longer than plain Selank.
Those impressions are reported practice, not data. The lower community doses, around 100 to 300 mcg once or twice daily, exist because users assume the longer-acting claim is true. Nobody has measured the analog's duration in humans.
Alias drift makes threads hard to read: names like NASA Selank can point at native Selank, N-acetyl Selank, or the amidate depending on the seller. Two people comparing experiences may be describing different molecules.
Product comparisons are unusually detailed for this family: vial sizes, peptide content, water and acetate percentages, whether a COA's lot matches what shipped. That scrutiny is warranted, and it is also an admission that identity cannot be taken for granted.
Use context
Routes, doses, and cycle patterns
The concrete schedule information is mostly for native Selank. The amidated analog has market presence, but the cited sources do not include an amidate-specific human regimen.
Human studies and product labels
Native Selank Russian nasal-drop label
- Purpose
- Anxiety and neurasthenic disorder labeling for the parent peptide
- Context
- Russian native Selank label and drug listings
- Route
- Intranasal
- Amount
- 2 drops into each nasal passage
- Frequency
- 3 times daily
- Duration
- Native Selank label: 14-day course; cited label describes possible repeat courses after 1 to 3 weeks. This is parent-peptide labeling, not an amidate regimen.
This is the clearest labeled route, amount, frequency, and duration in the listed label material. It applies to native Selank 0.15% nasal drops, not to N-Acetyl Selank Amidate.
Native Selank anxiety-asthenic patient study
- Purpose
- Anxiety-asthenic disorder immunomodulation context
- Context
- PubMed-indexed native Selank patient study
- Route
- Not described in the PubMed summary
- Amount
- Not described in the PubMed summary
- Frequency
- Not described in the PubMed summary
- Duration
- 14 days
The PubMed summary describes cytokine-balance findings over 14 days. It is parent-compound evidence and does not provide an amidate-specific dose schedule.
Native Selank comparator studies
- Purpose
- Anxiety-spectrum comparator context versus medazepam or phenazepam
- Context
- PubMed-indexed native Selank clinical papers
- Route
- Not described in the available summaries
- Amount
- Not described in the available summaries
- Frequency
- Not described in the available summaries
- Duration
- Not consistently described in the available summaries
These papers supply the main human proxy context for anxiety claims, but they are not a detailed native-Selank regimen that can be copied onto the amidated analog.
Native Selank animal mechanism schedules
- Purpose
- Mechanism and route-comparison context
- Context
- Preclinical native Selank papers
- Route
- Intranasal and other animal-study routes
- Amount
- 100 mcg/kg to 300 mcg/kg in animal-study summaries
- Frequency
- Single exposure or daily exposure depending on study
- Duration
- Single exposure or 5 days depending on study
These animal schedules help explain the research base, but they are not human dosing data and are not amidate-specific.
Real-world discussion
Community modified-analog ranges
- Purpose
- Anxiety and cognition discussion
- Context
- Nootropic vendors and forums
- Route
- Intranasal spray, with subcutaneous use also discussed
- Amount
- Most often around 100 to 300 mcg per administration, one to two times daily: lower than plain selank on the theory that the modified analog lasts longer.
- Frequency
- One to two times daily in most reports
- Duration
- Often described in 2 to 4 week runs
N-acetyl selank amidate is a vendor-modified analog with no published human literature; community amounts are extrapolations from plain selank, and the potency claim behind the lower range is untested. Reported as context, not a recommendation.
What varies
- Identity: native Selank, N-acetyl Selank, and N-Acetyl Selank Amidate are different evidence questions.
- Route: the parent label is intranasal; gray-market products may be sprays, powders, or vials with different assumptions.
- Amount: native label amounts and animal microgram-per-kilogram schedules are not a human amidate schedule.
- Claim type: anxiety, calm focus, potency, duration, and brain-penetration claims need exact analog support.
- Product quality: HPLC purity, peptide content, water, acetate, sterility, endotoxin, residual solvents, and storage are separate checks.
Human data
Human evidence
Every human citation on this page belongs to native Selank: the 62-patient comparison with medazepam, the 60-patient comparison with phenazepam, the cytokine study, the Russian label. For N-Acetyl Selank Amidate itself the reviewed record holds no randomized trials, no human pharmacokinetics, and no long-term safety data. Until those exist, potency, duration, and brain-penetration claims are market claims, however reasonable the chemistry behind them sounds.
Evidence maturity
Every human citation for this analog belongs to native Selank; the amidated molecule itself has no direct human evidence.
Small Russian anxiety-spectrum studies and a native Selank nasal-drop label provide the only human context.
N-terminal acetylation and C-terminal amidation are chemically plausible stability changes, not measured human advantages.
No human trials, pharmacokinetic studies, or long-term safety studies exist for the exact amidated molecule.
Gray-market sprays and powders sell potency and duration claims amid inconsistent identifiers and purity-content gaps.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Zozulia et al. native Selank comparator study | 62 patients with generalized anxiety disorder and neurasthenia | Comparator clinical study against medazepam, based on the PubMed summary | Native Selank, not amidated analog | The PubMed summary reports similar anxiolytic effects to medazepam, with additional antiasthenic and psychostimulant effects. | Native Selank only; Russian-language paper; public details are limited; no N-Acetyl Selank Amidate arm. | limited human proxy |
| Uchakina et al. native Selank immunomodulation study | Patients with anxiety-asthenic disorders | Patient biomarker study | Native Selank, not amidated analog | The PubMed summary describes Th1/Th2 cytokine-balance changes over 14 days and suggests immunomodulatory effects. | Biomarker-heavy; exact sample size and endpoints were not fully visible in the public summary; no direct analog evidence. | limited human proxy |
| Medvedev et al. native Selank versus phenazepam | 60 patients with phobic-anxiety and somatoform disorders | Comparator clinical study | Native Selank, not amidated analog | Public summaries report anxiolytic and mild nootropic effects for native Selank, with better tolerability language versus phenazepam and an effect reportedly lasting a week after the last dose. | Native Selank only; older Russian comparator context; no placebo arm visible in the public summary; no amidated analog. | limited human proxy |
| Medvedev et al. native Selank optimization paper | Anxiety-disorder treatment context | Follow-up clinical investigation | Native Selank, not amidated analog | The PubMed summary reports earlier improvement on HDRS and fewer selected phenazepam side effects in the Selank plus phenazepam arm. | The adjunct design does not provide stand-alone Selank efficacy data. It does not study N-Acetyl Selank Amidate. | limited human proxy |
| Missing amidate-specific human evidence | No direct human population cited for exact N-Acetyl Selank Amidate | No direct human evidence found in the reviewed literature | Gray-market analog and reference material | No randomized human trials, direct human PK papers, or long-term safety studies are available for the exact amidated analog. | The cited public sources leave amidate-specific efficacy, PK, and long-term safety questions unanswered. | unclear |
Cautions
Safety and unknowns
- Long-term safety for N-Acetyl Selank Amidate was not characterized in the reviewed human evidence.
- The native Selank Russian label lists pregnancy, lactation, and age under 18 as contraindicated because clinical studies were not conducted in those groups; that is parent-compound label context, not analog-specific evidence.
- The native label lists allergic reactions and unpleasant taste as adverse reactions of unknown frequency and states that overdose cases were not registered.
- FDA discusses selank acetate in compounding-risk material with concerns about immunogenicity, aggregation, peptide-related impurities, and missing human safety information.
- Product route matters: intranasal drops, sprays, powders, reference materials, and possible injectable vials carry different contamination, concentration, excipient, and dosing-error risks.
- Benzodiazepine-replacement language is especially risky because dependence, withdrawal, sedation, interaction, and psychiatric-safety questions have not been directly resolved for this analog.
Product quality
A vial label is only a starting point
Market identifiers are inconsistent. Some listings reuse native Selank CAS or PubChem identifiers for the amidated analog, while others list different formulas, molecular weights, or no CAS assignment.
One amidate COA example reports HPLC-UV-MS identity confirmation and 99.60% HPLC purity with expected mass 792.46. That is useful analytical context but not a full sterility, endotoxin, storage, or clinical-quality package.
Another seller example separates 99.39% HPLC purity from 85.50% peptide content, 2.34% water, and 15.82% acetate content, showing why "purity" can be a misleading shortcut.
A product labeled "Selank Amidate" may not be comparable to native Selank nasal drops, N-acetyl Selank, or another amidate listing unless identity, content, salt/counterion, and lot testing are clear.
Exact identity
The evidence depends on whether the product is native Selank, N-acetyl Selank, or N-Acetyl Selank Amidate.
Public identifiers
CAS, PubChem, formula, and molecular-weight drift can signal that sellers are mixing parent and analog evidence.
Peptide content
HPLC purity does not tell the full peptide-by-mass amount when water, acetate, salts, sugars, or other counterions are present.
Sterility and endotoxin
A purity result leaves route suitability open unless sterility, endotoxin, excipients, concentration, and handling are also tested for the actual lot.
Stability and storage
Peptides can degrade, aggregate, or vary by shipping and handling conditions, and the analog has no regulated product label available here.
Mechanism
How it is proposed to work
Parent Selank is a tuftsin-derived peptide that appears to interact with stress and anxiety biology, including GABA-related signaling, monoamine-related pathways, immune cytokine balance, and peptide-enzyme effects. The amidated analog adds a chemistry hypothesis: terminal modification might change stability or exposure. Exact-analog brain exposure, duration, clinical effect, and safety still need direct human evidence.
Native Selank was designed by extending the tuftsin motif with Pro-Gly-Pro, a stability-oriented change in the parent peptide family.
A rat frontal-cortex gene-expression study connected Selank and GABA to related neurotransmission changes and discussed possible allosteric modulation of the GABAergic system.
Other parent-compound work discusses dopamine, serotonin, orexin-related expression, enkephalin-degrading enzymes, and cytokine effects in anxiety-asthenic patients.
The amidate rationale rests on N-terminal acetylation and C-terminal amidation, but no cited analog-specific human PK paper shows stronger, longer, or more brain-penetrating effects.
Native Selank PK is proxy context: the Russian label reports 92.8% intranasal bioavailability, plasma appearance within 30 seconds, brain tissue penetration, and plasma decline over 5 to 5.5 minutes, but those are not direct N-Acetyl Selank Amidate measurements.
FAQ
Common questions
Is N-acetyl selank amidate the same as selank?
No. It is a vendor-modified analog marketed as longer-acting. The modification has no published literature, so every claim for it is extrapolated from plain selank.
How are people using it in practice?
Commonly 100 to 300 mcg intranasally, one to two times daily — lower than plain selank on the theory that the analog lasts longer.
Is there any published evidence for it?
No published human or animal literature exists for the analog itself. Even its identity is vendor-defined rather than established in a pharmacopeia.
Details
Technical details
Sources
References
- 1.
PubChem Selank entry. PubChem, Selank.
Native Selank chemistry reference.
- 2.
Russian Selank label. Russian Selank label PDF.
Native Selank label PK, indications, contraindications, adverse effects, official regimen.
- 3.
Vidal Russian listings. Vidal Russian drug listings for Selank.
Current Russia marketing/registration context.
- 4.
Uchakina 2008 study. Uchakina et al., 2008, PubMed record.
Native Selank patient immunomodulation study.
- 5.
Medvedev 2014 study. Medvedev et al., 2014, PubMed/RUDN summaries.
Native Selank vs phenazepam.
- 6.
Medvedev 2015 study. Medvedev et al., 2015, PubMed record.
Native Selank follow-up clinical investigation.
- 7.
Volkova 2016 mechanism paper. Volkova et al., 2016, PMC full text.
Core mechanism paper.
- 8.
V'yunova 2014 mechanism summary. V’yunova et al., 2014, Neurochemical Journal summary.
GABA-binding modulation line.
- 9.
Enkephalinase mechanism papers. Enkephalinase-related Selank papers, 2001 to 2002.
Alternative mechanistic hypothesis.
- 10.
FDA peptide safety-risk page. FDA safety-risk page for certain bulk drug substances.
Risk framing for selank acetate in compounding.
- 11.
FDA Tailor Made warning letter. FDA warning letter to Tailor Made Compounding.
Enforcement context and 503A analysis.
- 12.
FTC claim guidance. FTC Health Products Compliance Guidance.
Claim substantiation standard.
- 13.
Amidate COA example. Third-party amidate COA from MZ Biolabs.
Identity and purity example for the exact analog.
- 14.
Gray-market product examples. Gray-market pages used to map product claims and identifier inconsistencies.
Product-market context; not evidence of efficacy.
- 15.
Forum anecdote set. Reddit/forum anecdote set.
Community-claim signals only; no direct efficacy data.